Asif Khan

Asif Khan

Company: AstraZeneca

Job title: Medical Therapy Area Lead – EGFR & IO – Lung Franchise

Seminars:

Panel Discussion: Addressing the Shortcomings of Developing NSCLC-Targeted Therapies 8:30 am

Patient population response differences and how to overcome these What design elements are most optimal to achieve clinical benefit? The push to early disease: what will this entail? How can the mechanism of action be predicted for each patient and thus inform dosing strategies?Read more

day: Day One

Then and Now: NSCLC Therapies 8:00 am

This session will summarize the recent advances in advanced/ metastatic NSCLC therapeutics with a specific focus on emerging drug candidates (in early-phase I/II clinical trials) and highly anticipated combination studies.Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.